BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced on Monday that it has named Emile Nuwaysir, PhD as its new board chair, effective 1 August 2021.
Presently, Nuwaysir is the BlueRock Therapeutics president and CEO. He joined the company in 2020. The company said that he has experience building a small biotech and deep understanding of how to work and thrive within a large pharmaceutical ecosystem. He has brought various cellular therapies from invention to clinical testing.
In the new role, Dr Nuwaysir will continue to take an active role in the growth and maturation of the company, offering guidance and support on both corporate strategy and R&D.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer